{"filings":[{"id":748678,"accession_number":"0001493152-26-026415","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2026-05-29T21:00:24+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Calidi Biotherapeutics issues amended warrant for 17.4M shares at $0.23, subject to stockholder approval","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Issued amended warrant to accredited investor for 17,391,304 unvested shares at $0.23 exercise price.","Exercise conditioned on stockholder approval; minimum vesting acquisition amount increased to $1M from $500K.","Vesting termination date extended from July 8, 2026 to September 30, 2026.","Private placement exempt under Section 4(a)(2) and Rule 506(b); shares not registered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442916,"accession_number":"0001493152-26-023094","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2026-05-14T20:15:44+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics Q1 2026 net loss narrows to $4.4M; cash $6.6M, CLD-401 IND on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to common shareholders: $4.4M ($0.43/shr) vs $5.0M ($2.21/shr) in Q1 2025.","Cash and restricted cash $6.8M as of Mar 31, 2026; up from $5.8M at Dec 31, 2025.","G&A expenses fell $1.0M to $1.6M; R&D expenses rose to $2.6M from $2.4M.","CLD-401 IND submission expected by end of 2026; AACR data showed T, NK, and γδ T-cell activation.","Entered partnership with TransferAI to use AI platform to streamline CLD-401 IND submission."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96294,"accession_number":"0001493152-26-022024","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Calidi Biotherapeutics issues warrant for 17.4M shares at $0.23 in private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Warrant to purchase up to 17,391,304 shares of common stock at $0.23 per share issued to accredited investor.","Warrant first exercisable on September 8, 2026; vesting tied to future registered issuances of up to $4.0M.","Registered issuances may occur before July 8, 2026 but neither party is obligated to complete them.","Issuance exempt under Section 4(a)(2) and Rule 506(b) based on investor's accredited status.","Shares issuable upon exercise are restricted; no registration statement filed for resale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96293,"accession_number":"0001493152-26-014951","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics director Allan Camaisa to step down at 2026 annual meeting; Board reduced to 5","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Allan J. Camaisa will not stand for re-election; term expires at 2026 annual meeting; no disagreement with company.","Board reduced from six to five directors effective at the 2026 annual meeting.","Scott Leftwich appointed to Audit Committee effective April 1, 2026.","Camaisa's departure is not due to any disagreement with company operations or policies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110061,"accession_number":"0001493152-26-013236","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics Q4 net loss $4.1M; FY net loss $25.6M; CLD-401 IND on track for end-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $4.1M ($0.57/sh); FY net loss $25.6M ($5.95/sh) vs $23.8M ($35.70/sh) in 2024.","Cash and restricted cash $5.8M at Dec 31, 2025, down from $9.8M a year ago; raised $6.5M in offering/ATM.","Partnered with Avance Clinical to initiate CLD-401 first-in-human trial in Australia; plans to file IND by end-2026.","Presented in situ T-cell engager data at AACR-IO; partnered with Matica Bio for GMP manufacturing of CLD-401."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110060,"accession_number":"0001493152-26-009701","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Calidi closes $6M public offering; existing warrants amended to $0.50 exercise price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $6.03M from 12,094,631 units sold (including full over-allotment exercise).","Each unit priced at $0.50 and consists of common stock (or pre-funded warrant) plus Series J (5 yr), K (1 yr) and L (6 mo) warrants.","Existing warrants for ~2.97M shares (Series G/H/I) amended to exercise price of $0.50 per share.","Company had 10,545,725 common shares outstanding as of March 11, 2026, post-offering.","Proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110059,"accession_number":"0001493152-26-005840","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics posts updated corporate presentation; details unknown","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company made updated presentation available on its website on February 6, 2026.","Presentation furnished as Exhibit 99.1 to this Form 8-K under Item 7.01 Regulation FD.","No specific financial or operational updates disclosed in the filing excerpt provided.","Presentation content not included in the available text; cannot assess material changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110058,"accession_number":"0001493152-26-004089","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics provides corporate update; debt reduced by $3.1M, IND planned for Q4 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Term debt and notes payable reduced to $0.7M at Dec 31, 2025, from $3.8M at Dec 31, 2024 (unaudited).","G&A expenses cut by $2.3M in first nine months of 2025 vs same period 2024.","Plans to file IND for CLD-401 in Q4 2026 targeting NSCLC, triple-negative breast, and head/neck cancer.","Expects proof-of-concept data for RedTail platform in non-oncology indications and BiTE delivery with T-cell amplifiers.","New CEO Eric Poma, PhD (appointed 2025) and CMO Guy Travis Clifton, MD bring biopharma experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126629,"accession_number":"0001493152-25-022349","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics reports Q3 net loss of $5.2M; cash at $10.4M after $6.9M offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.2M in Q3 2025; net loss attributable to shareholders $10.8M due to non-cash deemed dividend on warrants.","Basic/diluted EPS loss $2.21 vs $7.75 prior year; cash $10.4M plus $0.2M restricted at Sep 30.","Gross proceeds of $6.9M from underwritten public offering; total 2025 gross proceeds $23.0M.","Presented CLD-401 preclinical data at SITC; new Scientific Advisory Board with four experts established.","RedTail platform expands targeting capabilities and payloads; CLD-401 advancing to IND-enabling studies."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126628,"accession_number":"0001493152-25-021418","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Calidi presents positive preclinical data on CLD-401 at SITC; IND filing expected by end 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CLD-401 protected from immune clearance and replicates specifically in tumor cells after systemic administration.","Systemic CLD-401 achieves tumor IL-15 superagonist levels comparable to localized Anktiva dosing, with minimal systemic exposure.","IND-enabling studies ongoing; IND submission expected by end of 2026.","Company actively seeking strategic partnerships to accelerate clinical development.","Investor day held at SITC featuring experts Dr. Zamarin (Mount Sinai) and Dr. Wrangle (MUSC)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126627,"accession_number":"0001493152-25-020390","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["1.01","1.02","2.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics sells 75% stake in Nova Cell subsidiary for $6M; expects $0.5M annual cost savings","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold 22.5M shares (100% of its Nova Cell ownership) for $6M; consideration includes debt cancellation of ~$1.2M and deferred payments.","Nova Cell ceases to be a subsidiary; Calidi expects $0.5M/year in G&A expense reductions.","Company retains cell lines for own use; Nova Cell assumes certain liabilities and is prohibited from oncolytic virus uses.","Calidi also terminates prior IP assignment agreement with Nova Cell."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126626,"accession_number":"0001493152-25-019353","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics forms Scientific Advisory Board to advance RedTail platform and CLD-401","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["SAB members include Drs. Mace Rothenberg (ex-Pfizer CMO), Dmitriy Zamarin (Mount Sinai), John Wrangle (MUSC), David Curiel (WashU).","RedTail platform uses enveloped vaccinia virus overexpressing CD55 for systemic delivery of genetic medicines to tumor sites.","Lead candidate CLD-401, in IND-enabling studies, targets NSCLC, head & neck, and other cancers with high unmet need.","CLD-401 is designed to home to metastases, replicate only in tumor cells, and express IL-15 superagonist.","SAB will guide efficient development of CLD-401 into the clinic and advance RedTail platform utility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143400,"accession_number":"0001493152-25-014293","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Calidi eliminates CLO role; W. Pizarro Campbell departs Oct 17, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CLO position eliminated; Campbell's employment terminated Oct 17, 2025 as part of cost-reduction initiatives; no disagreement cited.","Campbell receives severance of $212,500 paid over six months, plus potential $85,000 bonus tied to Nova Cell transaction before Oct 31, 2025.","Campbell enters six-month consulting agreement at $250/hr (max 20 hrs/mo) starting Oct 18, 2025.","CFO Andrew Jackson appointed as Corporate Secretary effective Oct 17, 2025.","Separation agreement includes standard release, confidentiality, and non-disparagement clauses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143399,"accession_number":"0001641172-25-026066","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Calidi Bio posts updated corporate presentation; no specifics available","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company made an updated presentation available on its website on August 29, 2025.","Presentation content not included in filing; no material new facts disclosed.","Investors should refer to the company's website for the actual presentation details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143398,"accession_number":"0001641172-25-025273","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics closes $6.9M public offering with full over-allotment exercise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $6.9M from 1,922,764 common stock units and 1,528,000 pre-funded warrant units.","Each unit priced at $2.00 (common) or $1.999 (pre-funded); Series I warrants exercisable at $2.00 for 5 years.","Underwriters exercised 450,000-unit over-allotment option in full; Ladenburg Thalmann sole book-runner.","Proceeds for working capital, pre-clinical studies, and clinical trial preparation.","Directors and executive officers subject to 90-day lock-up agreements post-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143397,"accession_number":"0001641172-25-024190","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Calidi Biotherapeutics enters separation agreement with ex-President Boris Minev; $287,500 in payments","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Boris Minev ceased as President, Medical & Scientific Affairs and Section 16 officer effective July 29, 2025.","Separation agreement provides $100,000 negotiated bonus for NNV1 and SNV1 IND approvals and $187,500 severance over 6 months.","Company will pay COBRA premiums for 6 months.","Agreement includes standard release of claims and non-disparagement; effective after 7-day revocation period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143396,"accession_number":"0001641172-25-022791","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Calidi Q2 net loss narrows to $5.7M; FDA Fast Track for CLD-201; raises $4.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.7M ($1.99/share) vs $7.4M ($16.75/share) in Q2 2024; R&D $2.6M, G&A $3.1M.","Cash $5.3M at June 30, 2025, down from $9.6M at Dec 31, 2024; restricted cash $0.1M.","FDA Fast Track Designation granted for CLD-201 for soft tissue sarcoma; Phase 1 IND opened Q1 2025.","Raised $4.6M gross proceeds via warrant inducement; total 2025 raises $15.7M.","Preclinical data for CLD-401 (RedTail platform) presented at ASCO; IND expected by end 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143395,"accession_number":"0001641172-25-022592","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Calidi Biotherapeutics effects 1-for-12 reverse stock split effective August 4, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at ratio 1-for-12 became effective on August 4, 2025.","No fractional shares issued; rounding up to nearest whole share; authorized shares unchanged at 330M common, 1M preferred.","Stock continues trading under symbol CLDI on NYSE American with new CUSIP 320703408.","Company states reverse split aims to optimize market dynamics and broaden investor appeal.","All outstanding equity awards adjusted proportionally to reflect the reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143394,"accession_number":"0001641172-25-021039","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Calidi eliminates President role; approves 1-for-12 reverse stock split effective Aug 5, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Calidi eliminated the President, Medical & Scientific Affairs position held by Dr. Boris Minev, effective July 29, 2025; CMO Dr. Guy Travis Clifton assumes duties.","Reverse stock split at 1-for-12 ratio; shares expected to begin trading on split-adjusted basis on NYSE American at market open August 5, 2025.","Stockholders approved the reverse split on July 9, 2025; Board approved ratio on July 11, 2025; new CUSIP is 320703 408.","Fractional shares will be rounded up to the nearest whole share; no action required for book-entry or street name holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143393,"accession_number":"0001641172-25-018808","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Calidi shareholders approve reverse stock split and 3M-share equity plan increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected James Schoeneck (6.5M for) and George Peoples (6.6M for) as Class II directors.","Ratified CBIZ CPAs P.C. as auditor for FY2025 (15.6M for, 1.3M against).","Approved reverse stock split ratio of 1:2 to 1:19, with board discretion on exact ratio.","Approved amendment to 2023 Equity Plan increasing authorized shares from 393,780 to 3,393,780.","All four proposals passed; quorum of 53.26% of shares represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143392,"accession_number":"0001641172-25-018553","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics raises $4.6M via warrant exercise at $0.70/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$4.6M from immediate exercise of 6,595,000 warrants at $0.70/share.","New Series H warrants issued for up to 6,595,000 shares at $0.70, exercisable after 6 months.","7 warrant holders participated; closing expected July 10, 2025.","Net proceeds for clinical programs and working capital.","Ladenburg Thalmann acts as placement agent with 8% fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161563,"accession_number":"0001641172-25-010348","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Calidi reports Q1 net loss $5.0M; CEO transition to Eric Poma; FDA clears CLD-201 IND","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO transition: Eric Poma appointed CEO; 30+ yrs biopharma; raised >$250M at Molecular Templates.","FDA cleared IND for CLD-201 (allogeneic stem cell therapy) for solid tumors; CIRM non-dilutive funding.","Selected IL-15 superagonist as first payload for Redtail platform; IND filing expected H2 2026.","Q1 net loss $5.0M ($0.18/share) vs $7.2M ($2.03/share) in Q1 2024; R&D $2.4M, G&A $2.6M.","Cash $10.6M at March 31, 2025, up from $9.6M at Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161562,"accession_number":"0001641172-25-008365","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics replaces auditor Marcum with CBIZ after Marcum acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum resigned as independent auditor on April 30, 2025, following its acquisition by CBIZ.","Audit Committee approved CBIZ as new auditor for fiscal year ending December 31, 2025.","Marcum's reports for 2023 and 2024 included a going concern explanatory paragraph; no adverse opinions.","No disagreements or reportable events between the company and Marcum during the past two fiscal years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161561,"accession_number":"0001641172-25-005777","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["1.01","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Calidi appoints Eric Poma as CEO; Allan Camaisa resigns, remains director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Allan Camaisa resigned as CEO and Chairman, effective April 21, 2025; will stay as Class III director and CEO Emeritus.","Eric Poma, Ph.D. named CEO and Class I director effective April 22, 2025; previously CEO of Molecular Templates (MTEM).","Poma receives $535k base salary, target bonus up to 50% of base, and option grant for 726,412 shares vesting over 4 years.","Camaisa gets $500k separation over 12 months, COBRA for 12 months, $10k/month transition pay, plus possible incentives through Dec 2026.","James Schoeneck appointed Chairman; board size increased from 5 to 6 members."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161560,"accession_number":"0001641172-25-003501","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics appoints Dr. Guy Travis Clifton as Chief Medical Officer, Consultant and Advisor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective April 8, 2025; one-year term with monthly consulting fee of $20,833.33.","Dr. Clifton is a practicing surgical oncologist with 17+ years experience, previously CMO at Parthenon Therapeutics.","Appointment coincides with recently filed IND for CLD-201 dose escalation trial in solid tumors.","Dr. Clifton has over 80 peer-reviewed publications and served as U.S. Army Colonel with four Afghanistan deployments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161559,"accession_number":"0001641172-25-001969","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics closes $3.9M registered direct offering and private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$3.9M from sale of 3.325M shares at $0.65 and pre-funded warrants for 2.728M shares.","Issued Series G warrants to purchase up to 6.053M shares at $0.6954, exercisable after 6 months for 7.5 years.","Ladenburg Thalmann placement agent; 8% cash fee + 1% management; received warrants for 302,650 shares at $0.8125.","Proceeds for working capital and to advance pre-clinical and clinical programs.","Directors/officers subject to 90-day lock-up; company restricted from further issuances for 75 days (with exceptions)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179707,"accession_number":"0001641172-25-001822","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics reports Q4 net loss of $4.1M; files IND for CLD-201 solid tumor trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net loss $4.1M ($0.27/share) vs $8.2M loss ($0.23/share) in Q4 2023.","Full year 2024 net loss $23.8M ($2.97/share) vs $29.2M ($17.33/share) in 2023.","Cash and restricted cash $9.8M as of Dec 31, 2024, up from $2.1M as of Dec 31, 2023.","IND filed in March 2025 for CLD-201 Phase 1 trial in solid tumors (breast, head&neck, sarcoma).","CLD-101 Phase 1 trial for high-grade glioma started recruiting at Northwestern; 14th patient treated at City of Hope."],"consensus_eps_estimate":-1.8115,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179706,"accession_number":"0001493152-25-009731","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics reports preclinical data: systemic RTNova platform delivers gene therapy payload to tumors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RTNova platform demonstrated killing of over 60 different tumor cell lines in preclinical models.","Single dose of 3KO RT with immunotherapeutic payload increased leukocyte infiltration to 92% vs 46% untreated.","Complete eradication of certain tumors observed in preclinical model after treatment with 3KO RT plus payload.","Platform also acts as a viral vector to express therapeutic genes at tumor sites; potential partnerships noted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179701,"accession_number":"0001493152-25-005699","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K/A","filed_at":"2025-02-10T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Calidi Biotherapeutics files 8-K/A to add auditor consent to Jan 10 filing","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment solely adds Exhibit 23.1, consent of Marcum LLP.","No modifications to prior 8-K disclosure; no new financial or operational data.","Filing date Feb 10, 2025; original report filed Jan 10, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179705,"accession_number":"0001493152-25-004887","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics ups ATM offering capacity to $11.2M, adds $6.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increased maximum ATM offering from $5.1M to $11.2M under existing sales agreement.","Filed prospectus supplement for $6.1M of common stock; $5.0M already previously sold.","Move provides additional equity capital for company's ongoing operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179704,"accession_number":"0001493152-25-003916","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["1.02","2.02","7.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics terminates SEPA with Yorkville; year-end cash $9.6M","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Terminated Standby Equity Purchase Agreement with Yorkville effective Jan 23, 2025; no shares ever issued under $25M facility.","Preliminary unaudited cash balance at Dec 31, 2024: approximately $9.6 million.","Q4'24 capital: $9.5M from public offerings, $2.0M from warrants, $3.1M from ATM; additional $4.25M in Jan 2025.","CEO states termination removes potential stock overhang, supports shareholder value.","IND cleared for CLD-101 Phase 1b/2 trial for high-grade glioma; enrollment to start Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179703,"accession_number":"0001493152-25-001711","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Calidi refiles FY2023 financials to reflect 1-for-10 reverse stock split","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["1-for-10 reverse stock split effective July 15, 2024, retroactively applied to FY2023 statements.","Exhibits incorporated by reference from December 12, 2024 S-1; no change to non-split information.","All other 2023 Annual Report information remains unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179702,"accession_number":"0001493152-25-001567","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics prices $4.25M public offering of 5M shares at $0.85/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced public offering of 5,000,000 shares at $0.85 per share for gross proceeds of $4.25 million.","Ladenburg Thalmann acting as exclusive placement agent; fees include 8% cash fee plus 1% management fee.","Placement agent warrants issued to purchase 250,000 shares at $1.0625 per share (125% of offering price).","Lock-up agreements: company 15 days, directors/officers 90 days from closing; agent may waive.","Net proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196446,"accession_number":"0001493152-24-046434","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Calidi presents RTNova data supporting systemic targeting of metastatic lung cancer at IOVC and SITC","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Data presented at IOVC and SITC shows RTNova enveloped virotherapy can target multiple metastatic tumor sites.","RTNova uses tumor-selective vaccinia virus engineered to produce high levels of EEVs to avoid immune clearance.","In an advanced lung metastasis model, RTNova demonstrated robust therapeutic potential as monotherapy and viral vector.","The platform can induce expression of engineered payloads in tumor cells, enabling future delivery of therapeutic genes.","Calidi plans to advance RTNova as a multi-modal systemic antitumor virotherapy and seek pharma collaborations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196445,"accession_number":"0001493152-24-046330","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics closes $7.5M public offering of 4.44M shares at $1.69/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$7.5M from 4,437,869 shares at $1.69; closed Nov 15, 2024.","Net proceeds for working capital, general corporate purposes, and pre-clinical/clinical trials.","Placement agent Ladenburg Thalmann gets 8% cash fee, 1% mgmt fee, and warrants for 221,893 shares at $2.1125.","Lock-ups: company 15 days, insiders 90 days; CEO may sell up to 10K shares after 25 days for tax planning.","Offering under effective S-3 shelf; proceeds expected to extend cash runway for clinical-stage biotech."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196444,"accession_number":"0001493152-24-044932","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics Q3 net loss widens to $5.1M; FDA clears NeuroNova IND","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.1M ($0.65/share) vs. $2.0M ($1.41/share) in Q3 2023.","R&D expenses $2.2M, down from $3.3M; G&A $3.1M, down from $4.0M.","Cash and restricted cash $2.1M as of Sept 30, 2024, unchanged from Dec 31, 2023.","FDA cleared IND for NeuroNova (CLD-101) Phase 1b/2 trial in high-grade glioma; trial expected early 2025.","Raised $2M in registered direct offering and private placement in October."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196443,"accession_number":"0001493152-24-042406","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics raises $2M in registered direct offering and private placement of warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 2,050,000 shares at $1.00 per share in a registered direct offering.","Concurrent private placement: Series E and F warrants to purchase up to 2,050,000 shares each at $1.13, exercisable after 6 months.","Gross proceeds ~$2 million; net proceeds for working capital and clinical trials.","Placement agent Ladenburg Thalmann receives 8% cash fee and warrants for 102,500 shares at $1.25.","Lock-up agreements: Company 30 days, directors/officers 90 days from closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196442,"accession_number":"0001493152-24-041633","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics posts updated corporate presentation on its website","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Calidi Biotherapeutics made an updated corporate presentation available on its website on October 18, 2024.","The presentation is intended for investor relations purposes and contains no new financial or clinical disclosures.","No material events such as M&A, leadership changes, or clinical milestones were reported in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196441,"accession_number":"0001493152-24-041623","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"NYSE American to delist Calidi Biotherapeutics warrants due to low trading price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NYSE Regulation commences delisting of Calidi warrants (CLDI WS) under Section 1001 of NYSE American Company Guide.","Each warrant exercisable for 1/10th of a share at $115.00 per whole share; trading suspended immediately.","Company has right to appeal to Listings Qualifications Panel; common stock (CLDI) remains listed on NYSE American.","Delisting does not affect business operations or SEC reporting obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196440,"accession_number":"0001493152-24-040953","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2024-10-11T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics enters $5.1M ATM equity offering with Ladenburg Thalmann","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company may sell up to $5.1M of common stock through ATM facility with Ladenburg Thalmann.","Commission of 3.0% on gross proceeds; expenses up to $50k reimbursable.","Shares sold at market prices; offering pursuant to effective S-3 registration statement.","Company not obligated to sell any shares; can suspend at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212743,"accession_number":"0001493152-24-038718","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA clears IND for Calidi's CLD-101 Phase 1b/2 trial in high-grade glioma","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared Northwestern University's IND for CLD-101, a stem cell-based oncolytic virus therapy for high-grade glioma.","Phase 1b/2 trial will evaluate safety/feasibility of multiple doses in newly diagnosed patients; expected to start Q1 2025.","Prior Phase 1 trial showed median overall survival 18.4 months and no dose-limiting toxicity (Lancet Oncology 2021).","Additional Phase 1 trial in recurrent high-grade glioma at City of Hope with interim data expected H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212742,"accession_number":"0001493152-24-037858","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2024-09-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Calidi Biotherapeutics elects Alan Stewart as director, ratifies auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of 57.57% (4,641,839 shares) present at Sep 20, 2024 annual meeting.","Alan Stewart elected Class I director with 2,055,631 votes for; 2,586,208 abstentions, no against.","George Ng did not stand for re-election; Board reduced from 6 to 5 members, no vacancy.","Ratification of Marcum LLP as auditor passed with 4,547,883 for, 36,790 against, 57,166 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212741,"accession_number":"0001493152-24-035939","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics posts presentation on antitumor virotherapies after RedChip webinar","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation titled 'Systemic and Localized Antitumor Virotherapies' referenced during September 11, 2024 RedChip webinar.","Webinar webcast available on Company's website Events and Presentation page.","No specific financial, clinical, or operational updates disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212740,"accession_number":"0001493152-24-033579","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2024-08-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics posts presentation on new wholly owned subsidiary Redtail Biopharma","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation made available August 22, 2024 on company website.","Redtail Biopharma, Inc. is a new wholly owned subsidiary of Calidi Biotherapeutics.","No financial terms or strategic details disclosed in the 8-K or presentation excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212739,"accession_number":"0001493152-24-033215","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Director George Ng to step down at 2024 annual meeting; Board reduced to 5","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["George Ng will allow his director term to expire at the Company's 2024 annual shareholder meeting.","Board size reduced from six to five directors effective the date of the 2024 annual meeting.","Mr. Ng will continue as a strategic advisor and consultant to the Company.","Departure not due to any disagreement with Company operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212738,"accession_number":"0001493152-24-031718","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics reports Q2 2024 net loss of $5.8M; cash at $1.0M; launches Nova Cell subsidiary","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.8M ($1.40 per share) vs. $12.5M loss ($14.24 per share) in Q2 2023.","Cash and restricted cash total ~$1.0M as of June 30, 2024, down from $2.1M at Dec 31, 2023.","Launched Nova Cell subsidiary with $2M investment from Dr. Ronald Rigor; received additional $1M into Calidi.","Appointed Dr. George Peoples to Board of Directors and Dr. Mark Gilbert to Medical Advisory Board.","Received new U.S. patent for SuperNova technology; raised $2.5M from warrant exercises in July/August 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212737,"accession_number":"0001493152-24-029384","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics raises $3M from Dr. Ronald Rigor; launches Nova Cell subsidiary with $2M investment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Ronald Rigor invests $1M in Calidi via 698,812 shares at $1.431 and warrants for 600,000 shares at $1.90.","Dr. Rigor invests $2M in Nova Cell subsidiary for 25% fully-diluted equity; IP assigned to Nova Cell.","Dr. Rigor appointed to Scientific and Medical Advisory Board; receives 5,000 stock options.","Exclusive license for Philippines for AAA stem cells and CLD-201; initial revenue expected 2025.","Nova Cell to focus on regenerative medicine, cosmetics, orthopedics; Calidi retains oncology focus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212736,"accession_number":"0001493152-24-027867","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Calidi Biotherapeutics announces 1-for-10 reverse stock split effective July 15, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at a 1-for-10 ratio, effective 12:01 a.m. ET on July 15, 2024.","Stockholder approval obtained at special meeting on June 6, 2024; Board set ratio at 1:10.","No fractional shares will be issued; fractional shares rounded up to the next whole number.","Authorized shares of common stock remain unchanged at 330,000,000 shares.","Trading symbol remains CLDI; new CUSIP number for common stock is 320703309."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212735,"accession_number":"0001493152-24-026477","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Calidi Biotherapeutics secures $600K loan at 15% interest from Dennis Conklin","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan agreement with Dennis R. Conklin for principal amount of $600,000.","Note bears simple interest at 15% per annum, matures three years from July 2, 2024.","Interest payable annually after each calendar year; principal and remaining interest due at maturity.","Proceeds received on July 2, 2024; use of proceeds not specified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212734,"accession_number":"0001493152-24-026374","cik":1855485,"company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDI","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Calidi Biotherapeutics announces 1-for-10 reverse stock split effective July 15, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-10 ratio effective 12:01 a.m. ET on July 15, 2024.","Common stock to trade on split-adjusted basis under symbol CLDI starting July 15.","No fractional shares issued; fractional shares rounded up to nearest whole share.","Warrants adjusted: public warrants exercisable for 1/10th share at $115/whole share; private warrants exercise price x10.","New CUSIP for common stock: 320703 309; warrants CUSIP unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3688520.4288939056,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-07-05T23:59:59+00:00|212734"}